Cost-effectiveness of collaborative care for chronically ill patients with comorbid depressive disorder in the general hospital setting, a randomised controlled trial by Horn, E.K. (Eva) et al.
BioMed CentralBMC Health Services Research
ssOpen AcceStudy protocol
Cost-effectiveness of collaborative care for chronically ill patients 
with comorbid depressive disorder in the general hospital setting, a 
randomised controlled trial
Eva K Horn*1,4, Tjeerd B van Benthem2, Leona Hakkaart-van Roijen3, 
Harm WJ van Marwijk4, Aartjan TF Beekman1,4,5, Frans F Rutten3 and 
Christina M van der Feltz-Cornelis1,4,5
Address: 1Netherlands Institute for Mental Health and Addiction (Trimbos-institute), Utrecht, The Netherlands, 2Onze Lieve Vrouwe Gasthuis, 
Amsterdam, The Netherlands, 3Institute of Medical Technology Assessment, Erasmus Medical Centre, Rotterdam, The Netherlands, 4Free 
University Institute for Extramural Research, Amsterdam, The Netherlands and 5Department of Psychiatric Epidemiology and Department of 
Psychiatry, Free University, Amsterdam, The Netherlands
Email: Eva K Horn* - EHorn@trimbos.nl; Tjeerd B van Benthem - T.B.vanBenthem@olvg.nl; Leona Hakkaart-van 
Roijen - Hakkaart@bmg.eur.nl; Harm WJ van Marwijk - HWJ.VanMarwijk@vumc.nl; Aartjan TF Beekman - AartjanB@ggzba.nl; 
Frans F Rutten - F.Rutten@erasmusmc.nl; Christina M van der Feltz-Cornelis - CFeltz@trimbos.nl
* Corresponding author    
Abstract
Background: Depressive disorder is one of the most common disorders, and is highly prevalent in chronically ill
patients. The presence of comorbid depression has a negative influence on quality of life, health care costs, self-
care, morbidity, and mortality. Early diagnosis and well-organized treatment of depression has a positive influence
on these aspects. Earlier research in the USA has reported good results with regard to the treatment of depression
with a collaborative care approach and an antidepressant algorithm. In the UK 'Problem Solving Treatment' has
proved to be feasible. However, in the general hospital setting this approach has not yet been evaluated.
Methods/Design: CC: DIM (Collaborative Care: Depression Initiative in the Medical setting) is a two-armed
randomised controlled trial with randomisation at patient level. The aim of the trial is to evaluate the treatment of
depressive disorder in general hospitals in the Netherlands based on a collaborative care framework, including
contracting, 'Problem Solving Treatment', antidepressant algorithm, and manual-guided self-help. 126 outpatients
with diabetes mellitus, chronic obstructive pulmonary disease, or cardiovascular diseases will be randomised to
either the intervention group or the control group. Patients will be included if they have been diagnosed with
moderate to severe depression, based on the DSM-IV criteria in a two-step screening method. The intervention
group will receive treatment based on the collaborative care approach; the control group will receive 'care as usual'.
Baseline and follow-up measurements (after 3, 6, 9, and 12 months) will be performed by means of questionnaires.
The primary outcome measure is severity of depressive symptoms, as measured with the PHQ-9. The secondary
outcome measure is the cost-effectiveness of these treatments according to the TiC-P, the EuroQol and the SF-36.
Discussion: Earlier research has indicated that depressive disorder is a chronic, mostly recurrent illness, which
tends to cluster with physical comorbidity. Even though the treatment of depressive disorder based on the
guidelines for depression is proven effective, these guidelines are often insufficiently adhered to. Collaborative care
and 'Problem Solving Treatment' will be specifically tailored to patients with depressive disorders and evaluated in
a general hospital setting in the Netherlands.
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Approximately 15% of the Dutch population will experi-
ence a major depressive disorder (MDD) at least once in
their lifetime, and 6% have experienced an MDD in the
past year [1]. Murray and Lopez (Global Burden of Dis-
ease Study) stated that MDD will even become the second
major cause of disability-adjusted life years in 2020 [2].
Among chronically ill patients in general hospitals, the
prevalence of depression varies, ranging from 13% to 50%
[3-8]. Half of all patients with chronic obstructive pulmo-
nary disease (COPD) seem to experience clinically signif-
icant symptoms of depression and/or anxiety, and yet,
comorbid MDD is frequently not identified or appropri-
ately treated [3,5] MDD can impair the ability to seek and
adhere to treatment for other medical illnesses, which can
be hazardous because MDD frequently occurs in combi-
nation with a variety of other physical illnesses, including
heart disease, stroke, cancer, and diabetes [9].
Strong associations have been found between physical ill-
ness and MDD. The presence of a comorbid depressive
disorder has a strong influence on quality of life, self-care,
adherence to medication regimens and general function-
ing. It raises morbidity, mortality and health care costs if
combined with various chronic physical diseases [10-16].
A meta-analysis of twelve studies showed that the pres-
ence of MDD even triples the likelihood of non-adherence
to medical treatment recommendations and also
increases the risk of subsequent physical illness, disability,
and premature death [17,18].
MDD is actually considered to be a risk factor for the onset
of type 2 diabetes mellitus (DM) – depressed adults have
a 37% increased risk for the development of DM [19]. Fur-
ther studies have shown that higher levels of depression
were associated with an increasing prevalence and severity
of DM complications, such as insulin resistance, which is
strongly associated with the risk of coronary heart disease
[20]. MDD is one of the best predictors of hospitalization
rate in older diabetic patients and among diabetic patients
with a high score for depression there was even a 54%
higher mortality rate than among patients with lower
scores on the depression scale. However, this only applies
to diabetic patients [21,22]. Among patients with heart
problems the presence of depressive symptoms can be
considered a risk factor for mortality and impaired cardi-
ovascular outcome, in particular in patients with myocar-
dial infarction [23,24].
Numerous studies have found an association between
comorbid mental and physical disorders with higher
resource costs [12,25-27]. Panzarino even states that
MDD is one of the most costly illnesses in the USA [11].
When looking at more specific types of costs, i.e. number
of visits to a physician or the length of stay in a hospital,
however, the picture is less clear, and the findings are
inconsistent [25].
Outpatients of a general hospital often suffer from a
chronic condition. Competing demands might hamper
recognition of depression in the general hospital outpa-
tient setting in the case of chronically ill patients. Depres-
sion is still the most under-recognized and under-treated
psychiatric disorder in patients with a chronic illness [28].
In 2005, the multidisciplinary guideline for depression
was published in the Netherlands [29]. In this guideline,
several evidence-based methods of treatment for MDD are
listed, such as biological treatments, psychotherapeutic
interventions, and supporting and structuring interven-
tions. Although no specific attention was paid to the role
of physical comorbidity in the guideline, the presence of
physical comorbidity has been found to have no effect on
the choice of treatment for MDD nor does it have an
adverse effect on the outcome of treatment [30,31]
Early detection of mental or physical conditions that does
lead to effective treatment increases the possibility of
remission. The longer MDD remains untreated, the more
difficult the treatment becomes [32]. This is even more the
case with respect to serious comorbid physical illness,
because physical and mental disorders can negatively
influence each other's course. Nevertheless, Hyman states
that approximately 90% of patients respond positively to
an appropriate treatment if it is provided in the required
intensity and for the right length of time [33]. Simon
reviewed the social and economic burden of mood disor-
ders, and found that MDD is associated with significant
functional impairment [34]. However, he also found that
effective treatment helped to restore these functions. This
stresses the importance of educating physicians and
nurses in the diagnosis and treatment of psychiatric disor-
ders.
The organisation of care for comorbid physically and
mentally ill patients is challenging. New concepts inte-
grating medical and psychiatric treatment have been
designed to provide care for patients with complicated
medical and psychiatric disorders, so-called medical psy-
chiatric units (MPUs) [35]. Kishi and Kathol found that in
type IV type of these units, improvement in medical symp-
toms was comparable with improvement in general hos-
pital wards, but that the psychiatric symptoms improved
more [36].
A relatively new approach in the treatment of chronic ill-
nesses is the so-called disease management program
(DMP). A DMP can be defined as a co-ordinated unit of
clinical care for chronically ill patients who are still able to
actively participate in the intervention [37]. A DMP is aPage 2 of 14
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such as DM, arthritis, HIV/AIDS, and COPD. DMPs are
also currently available for the treatment of depression
[37]. Several studies have shown that a DMP for patients
suffering from depression is superior compared to care as
usual (CAU), in terms of reducing the severity of the
depression, enhancing quality of life, maintaining
employment, and adherence to medication (for at least 90
days). It has also been found to be cost-effective as well
[37-39].
In the USA, a new concept, the 'collaborative care inter-
vention' is developed [40]. Collaborative care is based on
the principles of disease management and involves three
main principles: firstly, active collaboration of the patient
with the treatment; secondly, chained care with a built-in
improvement cycle (also called 'stepped care'); and
thirdly, collaboration between various medical disci-
plines. Katon et al. found that a collaborative care inter-
vention, based on the 'Improving Mood-Promoting
Access to Collaborative Treatment' (IMPACT) of depres-
sion for older adults with DM, was associated with more
depression-free days and lower costs [41]. The IMPACT
intervention consisted of a behavioural activation inter-
vention, Problem Solving Treatment (PST) and antide-
pressant medication. The long-term effect of the
collaborative care intervention was still associated with
sustained improvement after 12 months in two-thirds of
the patients [40]. The intervention further resulted in
reducing the severity of the depression over time and
higher satisfaction with the care provided, compared to
patients receiving CAU [42]. Another study evaluating the
IMPACT intervention among older adults with and with-
out comorbid physical illnesses showed that treatment
was equally effective in both groups. Hence, the presence
of multiple comorbid physical illnesses had no effect on
the outcome of the treatment for depression [31].
In conclusion, patients with chronic physical illnesses
often experience depressive symptoms. MDD is not
merely a secondary side-effect of a physical illness, but
must be considered as a serious comorbid mental illness.
The presence of depression has a negative effect on quality
of life and increases morbidity, mortality and health care
costs. However, early diagnosis and well-organized treat-
ment of depression can have a positive influence on the
costs, course, and side-effects of depression. In physically
ill patients, the care has to be organized in such a way that
the link with the general health care treatment can be
good. Previous studies have shown that DMPs can be
implemented successfully in the treatment of several –
especially chronic – diseases; however, comorbid mental
illnesses are not addressed in current DMP programs.
The present study will focus on patients suffering from
three prevalent chronic physical diseases, namely DM,
COPD, and cardiovascular diseases (CVD). Earlier studies
have shown that these patients more frequently suffer
from depression, compared to the general population
[43-46] Treatment in a collaborative care intervention
package for depression has already been realised in pri-
mary care in the USA, and has been found to be more
effective than CAU. Treatment for depression will there-
fore be integrated in a collaborative care intervention
package incorporating the principles of DMPs for the
treatment of comorbid DM, CVD, and COPD. Outpa-
tients of a general hospital who visit the DM, CVD, or
COPD clinics and who have a comorbid depressive disor-
der will participate in this study. The collaborative care
intervention package will include contracting, PST, an
antidepressant algorithm, and manual-guided self-help,
according to the basic model of patient and provider
adherence-enhancing techniques. The interventions will
be tailored to patient preferences, and compared with
well-documented CAU. All treatments included in this
study have individually been proven effective. The
progress of the patient will be monitored and, if necessary,
the treatment will be adapted. DMPs have already been
proven to be effective and cost-effective as well. The goal
will be to determine whether collaborative care in the gen-
eral hospital is a feasible and profitable approach in terms
of effectiveness and cost-effectiveness, compared to CAU.
Methods/Design
Objective
The primary aim of the study is to assess the effectiveness
of a collaborative care model for major depressive disor-
ders in patients with DM, CVD, and COPD in the general
hospital outpatient setting. The secondary aim is to esti-
mate the cost-effectiveness of this treatment package.
Hypothesis
The hypothesis underlying this study is that a collabora-
tive care model for major depressive disorder for outpa-
tients in a general hospital setting with DM, CVD, and
COPD is more effective and more cost-effective than CAU.
Study design
The study consists of a two-armed randomised controlled
trial, with randomisation at patient level. The outcome
parameters will be measured by a blinded research assist-
ant.
The patients in the intervention group will receive collab-
orative care from a consultative psychiatric nurse (CPN)
and a psychiatrist in the department of psychiatry of the
participating hospital. The control group will receive CAU
from a general non-psychiatric nurse in the outpatient
department. If patients in the control group are referred toPage 3 of 14
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not received training will treat them. Hence, trained CPNs
will not influence the content of CAU, and will therefore
not influence the outcome of the intervention. Since the
patients and the CPNs are aware of the allocation, they
can not be blinded. The patients will be assessed by means
of self-report questionnaires, in order to avoid the occur-
rence of interviewer bias.
General outpatient clinic nurses will be trained in screen-
ing for depressive disorders, and will screen all patients
visiting the participating departments during the inclu-
sion period. Patients not visiting the departments during
the inclusion period will be screened by mail. See Figure 1
for a flowchart.
Recruitment of departments
The study has been set up in co-operation with the Onze
Lieve Vrouwe Gasthuis (OLVG) in Amsterdam. The diabe-
tes, cardiological, and pulmonary outpatient clinics of the
OLVG will participate in the study.
A psychiatrist will be trained to provide the collaborative
care intervention, together with a care manager. He will
receive training in contracting (together with the care
manager) and the antidepressant algorithm.
Consultative psychiatric nurses will be trained to provide
the collaborative care intervention in the role of care man-
ager. They will receive training in monitoring, care-man-
agement, PST, and contracting. The department nurses
will receive training in screening for depressive disorder.
The care managers in the intervention group will be
closely monitored by the research team, in order to ensure
that the intervention is provided correctly. There will be
no care manager for patients receiving CAU.
Recruitment of patients
All patients visiting the participating departments, who
have been diagnosed with a specific chronic disease, as
specified in their files, will be selected. Specific diagnoses
are: DM type II in the DM department, COPD in the pul-
monary department, and chronic heart failure or post-
InterventionFigur  1
Intervention. DM: Diabetes Mellitus, CVD: Cardiovascular Diseases, COPD: Chronic Obstructive Pulmonary Disease, CPN: 
Consultative Psychiatric Nurse, CAU: Care As Usual
CAU
(content not known yet) 
Care management by CPN. 
If needed antidepressant
protocol by psychiatrist.
Care as usual group
(at DM, CVD or COPD outpatient
clinic)
Intervention group 
(at department of psychiatry,
contracting by CPN and 
psychiatrist)
Randomisation
Screening by department 
nurse or by questionnaire
Outpatient clinic (DM, CVD, COPD)Page 4 of 14
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ment. Patients who meet the inclusion criteria and visit
the participating departments during the inclusion period
will receive an information letter, an informed consent
form and the screening questionnaire (depression sub-
scale of the 'Patient Health Questionnaire' – PHQ-9).
Patients who screen positive for depression will then
receive the baseline questionnaire. Patients who meet the
inclusion criteria, but do not visit the participating depart-
ments will receive a package by mail which includes an
information letter, an informed consent form, the screen-
ing instrument (PHQ-9), and the baseline questionnaire.
In the information letter the patients are asked if they are
willing to participate in a Trimbos Institute study investi-
gating mental problems and treatment options in the gen-
eral hospital setting. If they agree to participate, they will
be asked to sign the informed consent form and to return
it together with the completed questionnaires to the
researchers.
Patients will be included in the study if they reach a cut-
off score of 15 (moderate to severe depressive disorder)
on the PHQ-9 [47]. For patients who reach the cut-off
score, the MINI-International Neuropsychiatric Interview
(MINI) will also be held by telephone to classify the
symptoms [48,49] The MINI is a brief validated and struc-
tured diagnostic psychiatric interview to assess DSM-IV
and ICD-10 psychiatric disorders.
In the same interview, the patients will be asked if the
symptoms have been present for at least 6 weeks, can be
diagnosed as major depressive disorder, and lead to gen-
eral dysfunction with serious problems in at least one of
the following: work, household, activities, or relationship.
Therefore, the aim is to include chronically ill patients
with a moderate to severe depressive disorder who dys-
function due to the depressive disorder.
For patients who are assigned to the intervention group a
consultation will be arranged, first with the care manager
and then with a psychiatrist, to provide more information
about the treatment and to formulate a treatment plan
together (contracting). Patients assigned to the CAU
group will be told that they can consult their general prac-
titioner if they feel that they need treatment, and they will
be monitored (see Figure 2 for a schematic diagram).
Patients will only be included in the study after they have
given written informed consent. The Medical Ethical
Committee of the Onze Lieve Vrouwe Gasthuis has
approved the trial (study no WO06-066).
Patient exclusion criteria
Patients will be excluded from the study if they: have
insufficient knowledge of the Dutch language to fill in the
questionnaires, have a serious mental impairment, are
already receiving psychiatric treatment, suffer from
dementia, delirium or bipolar disorder, are addicted to
drugs or alcohol, are psychotic or suicidal, and/or are
under 18 years of age.
Randomisation
Patients in the participating departments who screened
positive on the PHQ-9 and who have an MDD, according
to the MINI, will be randomly allocated to the interven-
tion group or the CAU group within their policlinic. Ran-
domisation will be performed by the researcher, using a
computerized method to avoid assignment bias. The
patients will not be blinded for their group allocation.
Embedding in the general hospital care setting
The collaborative care framework used in this study will
last for a maximum of 22 weeks, and comprises the fol-
lowing four elements: a) contracting, b) antidepressant
medication, c) PST, and d) manual-guided self-help.
These treatments are superimposed on the basic model of
patient and provider adherence-enhancing techniques.
The diabetes, cardiology, and pulmonary outpatient clin-
ics of the OLVG will participate in this study. The elements
of the collaborative care framework are divided among
different disciplines in order to maximize effect of the
interventions. The elements provided by each discipline
performing the elements are shown in Table 1:
Intervention
The intervention is based on a collaborative care model
[40,50-52]., which involves three main principles:
1. Active collaboration of the patient with the treatment. In
order to investigate the motivation of the patient, the psy-
chiatrist has to ask himself the following question: What
should I do to motivate the patient to participate in this
study? This principle will be addressed in the contracting
phase by the psychiatrist.
2. Chained care with a built-in improvement cycle (also called
'stepped care'). This means that each individual step which
is taken in the treatment will be evaluated. Based on the
results, the next step will be undertaken, tailored to the
patient's needs by the psychiatrist and the CPN.
3. Collaboration between various medical disciplines. The
medical specialists, the department nurses, the CPNs, and
the psychiatrist all work together in the diagnosis and/or
treatment of the patient.
Training
Since the treatment involves a collaborative care
approach, the psychiatrist participating in the study will
receive training in collaborative care, i.e. contracting andPage 5 of 14
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Flowchartigure 2
Flowchart. PHQ-9: Patient Health Questionnaire, MINI: MINI-International Neuropsychiatric Interview
Excluded
Suicidal, psychotic, serious
mental impairment, delirium,
dementia, language problems,
drug/alcohol addiction and/or
already psychiatric treatment
Excluded
Not meeting DSM-IV
criteria for major
depressive disorder
Excluded
PHQ-9 negative
(<15) or no response
T3 questionnaires
(9 months)
T3 questionnaires
(9 months)
T4 questionnaires
(12 months)
T4 questionnaires
(12 months)
T2 questionnaires
(6 months)
T2 questionnaires
(6 months)
T1 questionnaires
(3 months)
T1 questionnaires
(3 months)
Allocated to care as 
usual N=63
Allocated to 
intervention N=63 
Randomisation
2nd informed consent
MINI interview
N=630
1st informed consent, screening & 
baseline measurement (T0)
N= 6300 to outpatients of the
participating departments who have a 
specific chronic disease
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tion as care manager will receive training in monitoring,
care-management, PST, and contracting at the start of the
study and the department nurses will receive training in
screening for depression.
The training will be provided by members of the research
group who, in turn, were trained by the IMPACT research
group from Seattle, the developers of the collaborative
care model used in this study [53].
Treatment of patients in the intervention group
In the collaborative care framework used in this study, active
collaboration of the patient with the treatment is
enhanced. The care is tailored to the patient's needs
within an active team, which consists of the patient, the
care manager and the consulting psychiatrist. If the care
manager experiences difficulties in this process, (s)he can
consult the psychiatrist. Within the team the need for and
assessment of the required treatment will be determined,
and a treatment plan will be formulated. Subsequently,
the care managers will co-ordinate the care and evaluate
each step, together with the patient. According to the
stepped care principle, treatment response will be moni-
tored once every two weeks [54]. If necessary, each treat-
ment step will be followed by a subsequent step to
improve the outcome. For patients who solely receive PST,
this subsequent step can involve six extra sessions of PST
and/or adding antidepressant medication (AD), or
switching to antidepressant medication only. The same
method will be applied to patients who are treated with
both PST and antidepressant medication.
The framework also includes patient and provider adher-
ence-improving techniques. Provider adherence-improving
interventions are administered by the research group. Pro-
vider adherence has been enhanced in an earlier study in
primary care, in which psychiatrists instructed general
practitioners by means of consultations, combined with
phone calls and written instructions that were distributed
regularly [55]. Such an approach was also found to be fea-
sible and effective in the USA [56]. In the present study,
the adherence of care managers will be improved in a sim-
ilar way. Patient adherence will be improved by contract-
ing and psycho-education [55,57].
In the present setting, the collaborative care framework
includes four treatment options superimposed on adher-
ence-enhancing techniques. The patients will have the
choice of receiving antidepressant medication, but PST,
contracting and manual-guided self-help are obligatory.
Ad a) Contracting
The care manager and the consultant psychiatrist in the
hospital together inform the patient that the diagnosis is
a depressive disorder. The patient will receive psycho-edu-
cation about the course and the treatment options, and is
offered the choice of evidence and guideline-based treat-
ments. Depending on the patient's preferences, a joint
treatment contract is formulated by the psychiatrist, the
care manager and the patient. The aim of the contract is to
make clear that the treatment arrangements must be
adhered to by all parties involved. In an earlier study in
the Netherlands, based on a collaborative care model, col-
laboration was indeed enhanced by contracting [55].
During the intervention phase, the patient is asked to fill
in the PHQ-9 ahead of every appointment in order to
evaluate the progress. The treatment steps are evaluated
with the care manager. If a patient is not satisfied with the
chosen treatment, (s)he can change to another form of
treatment, and this will be confirmed in a new contract. If
a patient wishes to withdraw from the intervention, (s)he
will continue to receive CAU. All treatment choices are
well documented as process measures.
Ad b) Antidepressant algorithm
An earlier study in the USA reported that only 46% of out-
patients with care management who were treated with
antidepressants at their local academic medical centre
received adequate antidepressant treatment, thus reflect-
ing a minimum standard of treatment [58]. There are fur-
ther indications that chronically ill patients may require
individually tailored antidepressant treatment [59].
Therefore, to enhance efficiency and adherence to the
medication, a step-up antidepressant algorithm will be
tailored to patients with DM, CVD, and COPD, consisting
of two different types of antidepressant medication, i.e.
selective serotonin reuptake inhibitors (SSRIs) and tricy-
clic antidepressants (TCAs).
Two antidepressants will be tested in two periods of nine
weeks. If, after 18 weeks there is no improvement, the
patient will be offered different kinds of treatment. In the
choice of antidepressants, interactions with medication
for chronic illnesses and potential palliative side-effects
have been taken into consideration. If a patient is already
taking antidepressants, but is still suffering from depres-
Table 1: Embedding in the hospital setting
Task Discipline
Screening Department nurse/Researcher
Contractor Psychiatrist/Consultative psychiatric 
nurses
Care manager Consultative psychiatric nurses
Prescription of 
antidepressants
Psychiatrist
Problem Solving Treatment Consultative psychiatric nursesPage 7 of 14
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after the required wash-out period of several weeks, the
algorithm will commence. The PHQ-9 will be used to
screen for and monitor the course of depression. The fea-
sibility of the PHQ-9 to evaluate and guide a step-up algo-
rithm has already been proven in outpatients in the
primary care setting [40,60] Therefore, in the present
study, the PHQ-9 will be used in the same way. The care
managers will discuss the effects of the medication and
the potential side-effects with the patient, and report to
the psychiatrist. The psychiatrist will follow this process
closely to determine whether the treatment is satisfactory.
Earlier studies have shown that the prescription of antide-
pressants for patients suffering from DM type I and II is
safe and effective. Certain SSRIs, such as duloxetine, may
also even be effective in the treatment of painful diabetic
neuropathy [61,62]. However, knowledge about the inter-
action and side-effects of antidepressants in chronically ill
patients has not yet been structured into a protocol tai-
lored to the needs of patients with DM, CVD, and COPD.
Ad c) Problem Solving Treatment (PST)
Hawton and Kirkhave developed a brief psychological
intervention based on the Problem Solving Therapy by
D'Zurilla et al. [63] that uses the behavioural perspective,
but is less time-consuming [64]. PST will be administered
by nurses in 6–12 sessions, depending on the progress
according to the PHQ-9 scale. The problem-solving
approach consists of seven stages, and is based on the
assumption that emotional problems are often induced
by problems in everyday life.
Problem Solving Treatment has been found to be effective
for treating MDD when provided by trained community
nurses [65]. It is further significantly more effective than
placebo treatment, and also more effective than antide-
pressant medication alone for patients in primary care
[66].
The first session of PST will last for one hour, in which a
clear focus of the treatment is established, based on the
patient's current problems. Follow-up sessions will last for
thirty minutes.
Ad d) Manual-guided self-help
The patient will receive a standardised treatment manual,
specifically tailored to coping with depression and
chronic illness, and will work through this manual. It con-
sists of various chapters, focusing on relaxation, sleeping,
exercise and cognitions, and it also gives dietary sugges-
tions. The progress made by the patient is discussed every
week or every other week between the patient and the care
manager. Willemse et al. found that this kind of interven-
tion is more effective than CAU, at least for patients in pri-
mary care with a sub-clinical depression [67]. Relaxation
therapy on its own has been found to be useful as a com-
plementary approach to depression [29].
Patients suffering from depression often experience diffi-
culties in the sleep-wake-rhythm. The presence of these
difficulties is also one of the criteria in the classification of
MDD [68]. DM patients with painful peripheral neuropa-
thy were also found to suffer considerably from sleeping
problems[69]. For patients with chronic illnesses, sleep-
ing problems are significantly correlated with poorer
mental health, diminished work productivity and work
quality, and greater use of the health care services [70].
Hence, the treatment of sleeping problems will be an
important focus of this intervention.
Furthermore, exercise to improve general physical condi-
tion will be stimulated. Tkachuk and Martinhave exten-
sively reviewed studies focusing on exercise therapy for
patients with psychiatric disorders, and found that exer-
cise has a positive effect, among other things, on depres-
sion [71]. In chronically ill patients with comorbid
depression, exercise training was found to reduce the
severity of the depression and to have a positive influence
on indicators of illness risk factors [72-74]
The dietary intervention will focus on a healthy diet, los-
ing weight and on taking omega-3 fatty acids. McElroy et
al. concluded in their review that an overlap exists
between mood disorders and obesity [75]. Several studies
also indicate an association between omega-3 fatty acids
and depression. For example, Su et al. found that omega-
3 fatty acids could improve the short-term course of ill-
ness, and were well tolerated in patients with MDD [76].
The supplementation of omega-3 fatty acids was also
found to be helpful in treating depression in patients with
DM type 2 and in treating patients with heart diseases
[77,78]
Treatment of the patients in the control group
Half of the included patients function as a control group,
in which they will receive CAU. The actual content of the
CAU treatment (e.g. medication and number of contacts
with physicians) will be assessed with the 'Scale assessing
contacts between patients and practitioners' ('Contacten
met dokters en andere behandelaars') and the 'Scale
assessing medical utilization of health services' ('Vragenl-
ijst medische consumptie') [57].
Data collection
Data will be collected by the Trimbos Institute in co-oper-
ation with the Onze Lieve Vrouwe Gasthuis. After giving
informed consent, the patients will receive assessment
questionnaires by mail at baseline (T0), 3 (T1), 6 (T2), 9
(T3), and 12 months (T4) after inclusion. The modifiedPage 8 of 14
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recruit the patients.
Outcome parameters
The use of questionnaires in the hospital setting has a long
tradition. Several of the questionnaires used in this study
have already been used for earlier studies of patients in the
hospital setting (e.g. PHQ-9 [80], IDS-SR [81], SF-36 [82])
and proved feasible. Although physical symptoms such as
fatigue could be misinterpreted as depressive symptoms,
in outpatients with general physical disorders no other
diagnostic criteria for the diagnosis of MDD are needed
[83,84].
Baseline measurements will take place before inclusion
(T0). The first follow-up measurement will take place at
the end of the treatment, i.e. after 3 months (T1), and fur-
ther follow-up measurements will take place after 6 (T2),
9 (T3) and 12 months (T4).
1. Primary outcome measure
Severity of depressive symptoms
The severity of the depressive symptoms is the primary
outcome, and will be measured according to the depres-
sion sub-scale of the PHQ (PHQ-9). The PHQ-9 is a brief
instrument that scores each DSM-IV criterion of a major
depressive disorder on a scale ranging from zero (not at
all) to three (nearly every day) [47]. The PHQ-9 has been
found to be a valid and reliable instrument to measure the
severity of depression in patients with different medical
backgrounds [47]. In an earlier study, the PHQ-9 was used
successfully for the diagnosis of MDD in diabetic patients
[85].
An improvement of more than five points on the PHQ-9
can be considered a clinically relevant difference [86]. The
PHQ-9 will be administered at baseline and during treat-
ment at least every other week (before each appointment
with the care manager). After treatment, the PHQ-9 will
be administered every three months (3 (T1), 6 (T2), 9 (T3)
and 12 (T4) months after baseline).
2. Secondary outcome measure
Cost-effectiveness
In addition to the improvement of severity of symptoms,
the cost-utility of collaborative care compared to CAU is
assessed in this study. Therefore, an estimation of the
direct medical costs and the costs due to production losses
(productivity costs) is made. To estimate the costs the
'Trimbos/iMTA questionnaire for costs associated with
psychiatric illness' (TiC-P) is used [87,88] Quality of life is
assessed by the 'EuroQol' (EQ-5D) [89] and the 'Medical
Outcomes Study Short Form Health Survey – 36' (SF-36)
[90]. These are validated tools for measuring general
health-related quality of life.
The EQ-5D descriptive system consists of five dimensions
(mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression), each with three levels (no problems,
some problems, and extreme problems), thus defining
243 (35) distinct health states.
A recent study in the Netherlands measured and valuated
the EQ-5D, resulting in the 'Dutch EQ-5D tariff', which is
used to calculate utilities for EQ-5D health states for the
cost-utility analyses of Dutch health care programmes and
treatments [91,92]
The SF-36 is a self-administered questionnaire, designed
for use in clinical practice and research, health policy eval-
uations and general population surveys [90]. It assesses
eight health concepts: 1) limitations in physical activities
due to health problems, 2) limitations in social activities
due to physical or emotional problems, 3) limitations in
usual role activities due to physical health problems, 4)
bodily pain, 5) general mental health (psychological dis-
tress and well-being), 6) limitations in usual role activities
due to emotional problems, 7) vitality (energy and
fatigue), and 8) general health perceptions.
The cost-utility will be evaluated by relating the difference
in direct medical costs per patient, receiving either collab-
orative care or CAU, to the difference in terms of 'Quality
Adjusted Life Years' (QALY) gained, which yields a cost
per QALY estimate. Furthermore, we will also estimate the
cost per QALY, including the productivity costs.
3. Key effect modifier
Physical illness is considered to be the key effect modifier,
and will be measured according to the CBS list, a ques-
tionnaire developed by the Central Bureau for Statistics
(CBS) in the Netherlands. The CBS list contains 28
chronic conditions, ranging from DM type II to multiple
sclerosis.
4. Additional outcome measures and effect modifiers
Depressive symptoms will also be assessed with the 'Inven-
tory for Depressive Symptomatology-Self Report' (IDS-
SR) [81]. Remission (i.e. reduction in DSM-IV criteria
below the threshold for a diagnosis of depressive disorder
[68]) of depressive symptoms will be measured according
to the PHQ-9. Remission on the PHQ-9 is defined as a
score of five or below [86].
Somatoform presentation will be assessed with five ques-
tionnaires. Firstly, presentation will be assessed as the
number and intensity of functional somatic complaints a
patient reports on the 'Bodily Complaints Questionnaire'
('Lichamelijke Klachten Vragenlijst' [LKV]) [93]. Sec-
ondly, possible comorbid somatoform disorder will be
assessed with the 'Screening for Somatoform Symptoms –Page 9 of 14
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ured with the 'Whitley Index' (WI) [95,96]. Fourthly,
health anxiety and illness behaviour will be measured
with the 'Illness Attitude Scale' (IAS) [95]. Finally, pain
will be measured with one scale of the SF-36 and a visual
analogue scale (VAS).
Associated symptoms of comorbid chronic illness will be meas-
ured as fatigue, according to the Dutch version of the
'Multidimensional Fatigue Inventory' ('Multidimen-
sionele Vermoeidheids Index' [MVI-20]) [97,98] and as
disability with the 'World Health Organization-Disability
Assessment Survey-II' (WHO-DAS-II) [99].
Preference and adherence. Preferences of the patient will be
assessed according to the choices patients make in the
intervention group. Patient and provider adherence will
be assessed by means of a qualitative questionnaire [57].
The working relationship between the patient and the care
manager will be measured with the 'Helping Alliance
Questionnaire' (HAQ-II) [100], because the care manager
will provide PST [101]. The attitude of the care manager
towards the treatment of depressive disorder will be meas-
ured with the Depression Attitude Questionnaire (DAQ)
[102,103]
Life-events and social support will be assessed according to
the 'Social Readjustment Rating Scale' [104] to indicate
the amount of change in daily life, and by two items on
the SF-36 [90].
Personality traits will be measured according to the neurot-
icism and extraversion scales of the 'NEO Five-Factor
Inventory' (NEO-FFI), the abbreviated version of the NEO
personality inventory [105].
Treatment in the CAU group will be assessed with the 'Scale
assessing contacts between patients and practitioners'
('Contacten met doctors en andere behandelaars') and the
'Scale assessing medical utilization of health services'
('Vragenlijst medische consumptie') [57]. Both question-
naires measure the consumption of (medical) care of the
patient.
Power calculations
In this study, the PHQ-9 will be used as the primary out-
come measure. In order to detect a standardised difference
of 0.5 standard deviation in the primary outcome meas-
ure (which can be considered as a clinically relevant dif-
ference), 2 × 63 patients are needed when two-sided
testing and 80% power is assumed. Intention-to-treat
analysis will be applied. Therefore, 126 patients will be
needed. An improvement of more than five points on the
PHQ-9 can be considered a clinically relevant difference
[86].
Analyses
A collaborative care model for the treatment of major
depressive disorder in outpatients of a general hospital
setting with DM, CVD, and COPD is more effective and
more cost-effective than CAU, is the hypothesis underly-
ing the present study. The primary outcome is the effec-
tiveness in terms of the severity of the depressive
symptoms, as measured by the PHQ-9. The secondary
outcome is the cost-effectiveness, as measured with the
TiC-P, the EQ-5D, and the SF-36.
a. Effectiveness
Continuous outcome measures will be used to measure
the effectiveness of the present intervention. A t-test with
intention-to-treat analysis will be performed. When miss-
ing data arises, methods like 'last observation carried for-
ward' (LOCF) or 'multiple imputation' will be used. The
central effect modifier with regard to the effect of collabo-
rative care is comorbid chronic illness. Furthermore,
somatoform presentation, associated symptoms of
comorbid chronic illness, preference and adherence, life-
events and social support, and personality traits will be
included in the analysis as potential effect modifiers. The
effect size will be estimated by Chi-square analysis and
described in Cohen's d. Possible confounders, such as age,
gender, immigrant status, level of education, and treat-
ment history, will be included as variables in logistical
regression analysis.
b. Economic evaluation
The aim of the economic evaluation is to assess the cost-
effectiveness of collaborative care for the treatment of
depressive disorders in the general hospital setting. A cost-
utility analysis (CUA) will be applied, the results of which
will be expressed as cost per QALY. The economic evalua-
tion will be undertaken from a societal perspective, so all
relevant effects and costs due to resource utilisation
within the health care system (direct medical costs) and
costs due to production losses (productivity costs) will be
included.
Since the collaborative care intervention used in this study
is new intervention, a unit price per session is not known
yet. To determine a reference price, a detailed cost-price
study will be performed. Therefore, we will perform meas-
urements of time for face-to-face contacts as well as indi-
rect time per contact (e.g. consultations of other
specialists) for a total of 20 sessions. Furthermore, we will
estimate overhead costs based on the information of the
financial department of the hospital. This will result in an
estimate of the actual costs per contact. The unit cost esti-
mate per contact will be used as a reference price per con-
tact for the collaborative care intervention.Page 10 of 14
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iscommonly applied in economic evaluations of treat-
ments in mental health care. For instance, the TiC-P was
recently used in a large naturalistic trial on the cost-utility
of brief psychological treatment for depression and anxi-
ety [88].
Calculating the total direct medical costs, the total
number of medical contacts (outpatient visits, length of
stay in hospital, use of medication, etc.) will be multiplied
by unit costs of the corresponding health care services.
Reference unit prices of health care services will be
applied, and adjusted to the year of the study according to
the consumer price index [106].
The second section of the TiC-P includes a short form of
the Health and Labour questionnaire (HLQ) for collecting
data on productivity losses [107]. The Short-Form HLQ
(SF-HLQ) consists of three modules that measure produc-
tivity losses: absence from work, reduced efficiency at
work and difficulties with job performance [108]. The
number of days absent from work and the actual cost of
hours missed at work due to health-related problems are
valued according to the average value added per worker by
age and gender per day and per hour, respectively. If
respondents indicate that they have been absent for the
entire recall period, data will be collected from the time
when the period of long-term absence started. This addi-
tional information will be used to value the production
losses according to the friction cost method [109,110].
The friction cost method takes into account the economic
circumstances that limit the losses of productivity to soci-
ety, which are related to the fact that a formerly unem-
ployed person may replace a person who becomes
disabled [109].
For the economic evaluation, the effects will be measured
according to utility scores. In addition to the clinical out-
come parameters, the utility scores will supply additional
information about the impact of collaborative care on the
treatment of MDD compared to the impact of CAU on the
general health related quality of life. Furthermore, the
results can be compared to a broad range of other health
care interventions, also outside the field of mental health
care.
The cost-utility will be evaluated by relating the difference
in direct medical costs per patient receiving collaborative
care or CAU to the difference in terms of QALYs gained,
which yields a cost per QALY estimate. Furthermore, we
will also estimate the cost per QALY, including the pro-
ductivity costs.
In the case of missing data on costs and/or effects, and the
additional uncertainty this introduces, we will use 'multi-
ple imputation' [111]. We will use the Monte Carlo
Markov Chain (MCMC) approach to impute the missing
values. The uncertainty will be assessed with bootstrap-
ping, and the results will be presented in acceptability
curves [112].
Time-frame of the study
The preparatory period will be 6 months. After approval
has been received from the Medical Ethical Committee,
the care managers are trained. The inclusion and interven-
tion phase will take 22 months. The follow-up phases will
be 3 (T1), 6 (T2), 9 (T3), and 12 months (T4) after inclu-
sion. Data-analyses will take another 6 months, with
interim reporting every year. The entire study period will
last for 4 years.
Ethical principles
The study has been planned, and will be carried out in
accordance with the principles laid down in the Helsinki
declaration (Edinburgh, Scotland amendment, October
2000).
Participation in the study is voluntarily. The patients will
be informed in writing and verbally about the global fea-
tures of the study, the possible benefits of participating in
the experimental group, and the societal aspects of the
study. The patients will be explicitly informed of the fact
that they can withdraw their consent to participate at any
time, without specification of any reasons, and with no
negative consequences for their future treatment. Patients
who wish to withdraw from the study will receive CAU.
Informed consent will be obtained twice from the
patients. First, prior to completion of the baseline ques-
tionnaire, and again before inclusion in the study.
The names of the patients and other confidential informa-
tion will be treated according to the medical confidential-
ity rules and patient data will be separated from patient
names. The patients will be anonymous, because each
participant will be identified in the database by a number
and a code. The codes will only be available for the partic-
ipating investigators.
Furthermore, all study-related data will be stored on a pro-
tected Trimbos Institute server, access to which granted
exclusively to the members of the research team. The
investigators will be responsible for the administration of
the study. The results of the surveys will not be disclosed
to the hospital staff.
The Medical Ethical Committee of the OLVG has
approved of the study protocol (study no WO06-066).Page 11 of 14
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There is a high prevalence of chronically ill patients suffer-
ing from depression, and interventions for the treatment
of comorbid depression are urgently needed. Evidence for
effective treatment does exist, but these are frequently not
applied. The current trial is designed to implement evi-
dence-based treatments for depression in the general hos-
pital setting, and to test the hypothesis that these
treatments are more effective and cost-effective than CAU.
This is a pragmatic trial; hence, the objective of the trial is
to assess the benefits of the treatment in routine clinical
practice. The relationship between depressive symptoms
and the course of several chronic illnesses suggests that
this line of research may be of considerable importance in
the field of public health.
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